Add group to favorites
Back to post list
Send new message to group Search:
Post Subject:
Supplement alpha lipoic acid benefits neuropathy
Supplement alpha lipoic acid benefits neuropathy
Still it not used as widely as it should though it has been
know for a long time it has benefits in this context.
-------------------------------------------------------
1: Diabetes Care. 2006 Nov;29(11):2365-70.
Oral treatment with alpha-lipoic acid improves symptomatic diabetic
polyneuropathy: the SYDNEY 2 trial.
Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U,
Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R.
FRCPE, Deutsche Diabetes-Klinik, Deutsches Diabetes-Zentrum, Leibniz-
Institut an der Heinrich-Heine-Universität, Auf'm Hennekamp 65, 40225
Düsseldorf, Germany.
dan.ziegler@ddz.uni-duesseldorf.de
OBJECTIVE:
The aim of this trial was to evaluate the effects of alpha-lipoic
acid
(ALA) on positive sensory symptoms and neuropathic deficits in
diabetic patients with distal symmetric polyneuropathy (DSP).
RESEARCH DESIGN AND METHODS:
In this multicenter, randomized, double-blind, placebo-controlled
trial, 181 diabetic patients in Russia and Israel received once-daily
oral doses of 600 mg (n = 45) (ALA600), 1,200 mg (n = 47) (ALA1200),
and 1,800 mg (ALA1800) of ALA (n = 46) or placebo (n = 43) for 5 weeks
after a 1-week placebo run-in period. The primary outcome measure was
the change from baseline of the Total Symptom Score (TSS), including
stabbing pain, burning pain, paresthesia, and asleep numbness of the
feet. Secondary end points included individual symptoms of TSS,
Neuropathy Symptoms and Change (NSC) score, Neuropathy Impairment
Score (NIS), and patients'
global assessment of efficacy.
RESULTS:
Mean TSS did not differ significantly at baseline among the treatment
groups and on average decreased by 4.9 points (51%) in ALA600, 4.5
(48%) in ALA1200, and 4.7 (52%) in ALA1800 compared with 2.9
points (32%) in the placebo group (all P < 0.05 vs. placebo). The
corresponding response rates (>/=50% reduction in TSS) were 62, 50,
56, and 26%, respectively. Significant improvements favoring all three
ALA groups were also noted for stabbing and burning pain, the NSC
score, and the patients' global assessment of efficacy. The NIS was
numerically reduced. Safety analysis showed a dose-dependent increase
in nausea, vomiting, and vertigo.
CONCLUSIONS:
Oral treatment with ALA for 5 weeks improved neuropathic symptoms and
deficits in patients with DSP. An oral dose of 600 mg once daily
appears to provide the optimum risk-to-benefit ratio.
PMID: 17065669 [PubMed - indexed for MEDLINE]
Related Links
Treatment of symptomatic diabetic polyneuropathy with the
antioxidant
alpha-lipoic acid: a 7-month multicenter randomized controlled trial
(ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in
Diabetic Neuropathy.
[Diabetes Care. 1999]
PMID:10480774
The sensory symptoms of diabetic polyneuropathy are improved with
alpha-lipoic acid: the SYDNEY trial. [Diabetes Care. 2003]
PMID:12610036
Treatment of symptomatic diabetic polyneuropathy with the
antioxidant
alpha-lipoic acid: a meta-analysis. [Diabet Med. 2004]
PMID:14984445
Clinical experience with thioctacid (thioctic acid) in the
treatment of distal
symmetric polyneuropathy in Korean diabetic patients. [J Diabetes
Complications.
2004] PMID:15120701
Treatment of symptomatic diabetic peripheral neuropathy with the
anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized
controlled trial (ALADIN Study). [Diabetologia. 1995]
PMID:8786016
Still it not used as widely as it should though it has been
know for a long time it has benefits in this context.
-------------------------------------------------------
1: Diabetes Care. 2006 Nov;29(11):2365-70.
Oral treatment with alpha-lipoic acid improves symptomatic diabetic
polyneuropathy: the SYDNEY 2 trial.
Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U,
Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R.
FRCPE, Deutsche Diabetes-Klinik, Deutsches Diabetes-Zentrum, Leibniz-
Institut an der Heinrich-Heine-Universität, Auf'm Hennekamp 65, 40225
Düsseldorf, Germany.
dan.ziegler@ddz.uni-duesseldorf.de
OBJECTIVE:
The aim of this trial was to evaluate the effects of alpha-lipoic
acid
(ALA) on positive sensory symptoms and neuropathic deficits in
diabetic patients with distal symmetric polyneuropathy (DSP).
RESEARCH DESIGN AND METHODS:
In this multicenter, randomized, double-blind, placebo-controlled
trial, 181 diabetic patients in Russia and Israel received once-daily
oral doses of 600 mg (n = 45) (ALA600), 1,200 mg (n = 47) (ALA1200),
and 1,800 mg (ALA1800) of ALA (n = 46) or placebo (n = 43) for 5 weeks
after a 1-week placebo run-in period. The primary outcome measure was
the change from baseline of the Total Symptom Score (TSS), including
stabbing pain, burning pain, paresthesia, and asleep numbness of the
feet. Secondary end points included individual symptoms of TSS,
Neuropathy Symptoms and Change (NSC) score, Neuropathy Impairment
Score (NIS), and patients'
global assessment of efficacy.
RESULTS:
Mean TSS did not differ significantly at baseline among the treatment
groups and on average decreased by 4.9 points (51%) in ALA600, 4.5
(48%) in ALA1200, and 4.7 (52%) in ALA1800 compared with 2.9
points (32%) in the placebo group (all P < 0.05 vs. placebo). The
corresponding response rates (>/=50% reduction in TSS) were 62, 50,
56, and 26%, respectively. Significant improvements favoring all three
ALA groups were also noted for stabbing and burning pain, the NSC
score, and the patients' global assessment of efficacy. The NIS was
numerically reduced. Safety analysis showed a dose-dependent increase
in nausea, vomiting, and vertigo.
CONCLUSIONS:
Oral treatment with ALA for 5 weeks improved neuropathic symptoms and
deficits in patients with DSP. An oral dose of 600 mg once daily
appears to provide the optimum risk-to-benefit ratio.
PMID: 17065669 [PubMed - indexed for MEDLINE]
Related Links
Treatment of symptomatic diabetic polyneuropathy with the
antioxidant
alpha-lipoic acid: a 7-month multicenter randomized controlled trial
(ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in
Diabetic Neuropathy.
[Diabetes Care. 1999]
PMID:10480774
The sensory symptoms of diabetic polyneuropathy are improved with
alpha-lipoic acid: the SYDNEY trial. [Diabetes Care. 2003]
PMID:12610036
Treatment of symptomatic diabetic polyneuropathy with the
antioxidant
alpha-lipoic acid: a meta-analysis. [Diabet Med. 2004]
PMID:14984445
Clinical experience with thioctacid (thioctic acid) in the
treatment of distal
symmetric polyneuropathy in Korean diabetic patients. [J Diabetes
Complications.
2004] PMID:15120701
Treatment of symptomatic diabetic peripheral neuropathy with the
anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized
controlled trial (ALADIN Study). [Diabetologia. 1995]
PMID:8786016
Re: Supplement alpha lipoic acid benefits neuropathy
trigonometry1972@gmail . com | wrote:
> 1: Diabetes Care. 2006 Nov;29(11):2365-70.
>
> Oral treatment with alpha-lipoic acid improves symptomatic diabetic
> polyneuropathy: the SYDNEY 2 trial.
>
> OBJECTIVE:
> The aim of this trial was to evaluate the effects of alpha-lipoic
> acid (ALA)....
Let's call it thioctic acid. The temptation to abbreviate
alpha-lipoic acid to ALA is just too strong.
--
Marshall Price of Miami
Known to Yahoo as d021317c
trigonometry1972@gmail . com | wrote:
> 1: Diabetes Care. 2006 Nov;29(11):2365-70.
>
> Oral treatment with alpha-lipoic acid improves symptomatic diabetic
> polyneuropathy: the SYDNEY 2 trial.
>
> OBJECTIVE:
> The aim of this trial was to evaluate the effects of alpha-lipoic
> acid (ALA)....
Let's call it thioctic acid. The temptation to abbreviate
alpha-lipoic acid to ALA is just too strong.
--
Marshall Price of Miami
Known to Yahoo as d021317c
Re: Supplement alpha lipoic acid benefits neuropathy
On May 13, 2:19 pm, Marshall Price <d0213...@yahoo . com > wrote:
> trigonometry1...@gmail . com | wrote:
> > 1: Diabetes Care. 2006 Nov;29(11):2365-70.
>
> > Oral treatment with alpha-lipoic acid improves symptomatic diabetic
> > polyneuropathy: the SYDNEY 2 trial.
>
> > OBJECTIVE:
> > The aim of this trial was to evaluate the effects of alpha-lipoic
> > acid (ALA)....
>
> Let's call it thioctic acid. The temptation to abbreviate
> alpha-lipoic acid to ALA is just too strong.
>
> --
> Marshall Price of Miami
> Known to Yahoo as d021317c
Blame the party that wrote the abstract. But I do agree
that abbreviations and acronyms do leave alot to be desired.
It is context context on abbrevs ;-)
OK, I'll use thioctic acid a bit more as that is the first name I
learned
for this chemical back in the 60's. But when I cut and
paste an abstract it will be what they use that I write.
On May 13, 2:19 pm, Marshall Price <d0213...@yahoo . com > wrote:
> trigonometry1...@gmail . com | wrote:
> > 1: Diabetes Care. 2006 Nov;29(11):2365-70.
>
> > Oral treatment with alpha-lipoic acid improves symptomatic diabetic
> > polyneuropathy: the SYDNEY 2 trial.
>
> > OBJECTIVE:
> > The aim of this trial was to evaluate the effects of alpha-lipoic
> > acid (ALA)....
>
> Let's call it thioctic acid. The temptation to abbreviate
> alpha-lipoic acid to ALA is just too strong.
>
> --
> Marshall Price of Miami
> Known to Yahoo as d021317c
Blame the party that wrote the abstract. But I do agree
that abbreviations and acronyms do leave alot to be desired.
It is context context on abbrevs ;-)
OK, I'll use thioctic acid a bit more as that is the first name I
learned
for this chemical back in the 60's. But when I cut and
paste an abstract it will be what they use that I write.
